Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1949 1
1950 1
1953 3
1954 3
1955 3
1956 2
1957 2
1959 3
1960 2
1961 1
1962 3
1963 2
1964 1
1965 1
1966 1
1967 1
1968 2
1969 3
1970 5
1971 9
1972 15
1973 9
1974 17
1975 15
1976 10
1977 10
1978 10
1979 7
1980 6
1981 7
1982 7
1983 2
1984 5
1985 7
1986 12
1987 10
1988 11
1989 16
1990 13
1991 17
1992 14
1993 14
1994 23
1995 18
1996 24
1997 15
1998 22
1999 13
2000 11
2001 17
2002 12
2003 18
2004 14
2005 9
2006 7
2007 13
2008 9
2009 21
2010 17
2011 22
2012 18
2013 14
2014 19
2015 22
2016 19
2017 14
2018 15
2019 17
2020 17
2021 20
2022 14
2023 5
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

731 results

Results by year

Filters applied: . Clear all
Page 1
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Saußele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R. Hochhaus A, et al. Among authors: clark re. Leukemia. 2020 Apr;34(4):966-984. doi: 10.1038/s41375-020-0776-2. Epub 2020 Mar 3. Leukemia. 2020. PMID: 32127639 Free PMC article. Review.
The medial temporal lobe.
Squire LR, Stark CE, Clark RE. Squire LR, et al. Among authors: clark re. Annu Rev Neurosci. 2004;27:279-306. doi: 10.1146/annurev.neuro.27.070203.144130. Annu Rev Neurosci. 2004. PMID: 15217334 Review.
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saußele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R. Baccarani M, et al. Among authors: clark re. Blood. 2013 Aug 8;122(6):872-84. doi: 10.1182/blood-2013-05-501569. Epub 2013 Jun 26. Blood. 2013. PMID: 23803709 Free PMC article. Review.
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Boquimpani C, Pasquini R, Clark RE, Dubruille V, Flinn IW, Kyrcz-Krzemien S, Medras E, Zanichelli M, Bendit I, Cacciatore S, Titorenko K, Aimone P, Saglio G, Hochhaus A. Kantarjian HM, et al. Among authors: clark re. Leukemia. 2021 Feb;35(2):440-453. doi: 10.1038/s41375-020-01111-2. Epub 2021 Jan 7. Leukemia. 2021. PMID: 33414482 Free PMC article. Clinical Trial.
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial.
Brümmendorf TH, Cortes JE, Milojkovic D, Gambacorti-Passerini C, Clark RE, le Coutre P, Garcia-Gutierrez V, Chuah C, Kota V, Lipton JH, Rousselot P, Mauro MJ, Hochhaus A, Hurtado Monroy R, Leip E, Purcell S, Yver A, Viqueira A, Deininger MW; BFORE study investigators. Brümmendorf TH, et al. Among authors: clark re. Leukemia. 2022 Jul;36(7):1825-1833. doi: 10.1038/s41375-022-01589-y. Epub 2022 May 28. Leukemia. 2022. PMID: 35643868 Free PMC article. Clinical Trial.
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, Morgan YG, Lok J, Grech A, Jones G, Khwaja A, Friis L, McMullin MF, Hunter A, Clark RE, Grimwade D; UK National Cancer Research Institute Acute Myeloid Leukaemia Working Group. Burnett AK, et al. Among authors: clark re. Lancet Oncol. 2015 Oct;16(13):1295-305. doi: 10.1016/S1470-2045(15)00193-X. Epub 2015 Sep 14. Lancet Oncol. 2015. PMID: 26384238 Clinical Trial.
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.
Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre PD, Etienne G, Dorlhiac-Llacer PE, Clark RE, Flinn IW, Nakamae H, Donohue B, Deng W, Dalal D, Menssen HD, Kantarjian HM. Hochhaus A, et al. Among authors: clark re. Leukemia. 2016 May;30(5):1044-54. doi: 10.1038/leu.2016.5. Epub 2016 Feb 3. Leukemia. 2016. PMID: 26837842 Free PMC article. Clinical Trial.
Nail surgery.
Clark RE, Madani S, Bettencourt MS. Clark RE, et al. Dermatol Clin. 1998 Jan;16(1):145-64. doi: 10.1016/s0733-8635(05)70492-7. Dermatol Clin. 1998. PMID: 9460583 Review.
Dermatofibrosarcoma protuberans.
Garcia C, Clark RE, Buchanan M. Garcia C, et al. Among authors: clark re. Int J Dermatol. 1996 Dec;35(12):867-71. doi: 10.1111/j.1365-4362.1996.tb05053.x. Int J Dermatol. 1996. PMID: 8970843
The classical origins of Pavlov's conditioning.
Clark RE. Clark RE. Integr Physiol Behav Sci. 2004 Oct-Dec;39(4):279-94. doi: 10.1007/BF02734167. Integr Physiol Behav Sci. 2004. PMID: 16295771 Review.
731 results